Abstract: Poster Presentations |


Anand A. Dalal, PhD; Douglas W. Mapel, MD*; Christopher M. Blanchette, PhD; Hans Petersen, PhD
Author and Funding Information

Lovelace Respiratory Research Institute, Albuquerque, NM


Chest. 2009;136(4_MeetingAbstracts):89S. doi:10.1378/chest.136.4_MeetingAbstracts.89S
Text Size: A A A
Published online


PURPOSE:  Chronic Bronchitis (CB) is an earlier stage of chronic obstructive pulmonary disease (COPD) that is often misdiagnosed as acute bronchitis or smokers’ cough. By the time CB is diagnosed/treated, many patients have already progressed into more severe stages resulting in a higher consumption of healthcare resources and more difficulty in clinical management. The objective of this study was to determine the healthcare costs and resource utilization associated with the diagnosis of CB.

METHODS:  A retrospective cohort study was conducted using administrative claims data, CB patients aged > 40 years with > 12 months of pre-index and > 12 months of post-index continuous enrollment in one of the participating health plans of the PharMetrics database between July 1, 2003 –June 30, 2007. Index date was set as the first claim for an ICD-9-CM diagnosis code of 491.xx [patients with emphysema (492.xx) or COPD (496.xx) along with CB in pre-index period were excluded]. Controls were matched to CB patients at 1:1 (on age, sex, region, prior healthcare utilization, and comorbidities). Descriptive, bivariate, and multivariate statistics were used to assess difference between CB patients and controls in the post-index period (up to 24 months).

RESULTS:  6,828 CB subjects were matched to 6,828 controls. Of these, 4,295 (63%) CB subjects did not receive any treatment despite being diagnosed. Total unadjusted all cause costs in year 1 post-index for CB were $10,541, and $12,193 in year 2 compared to $5,285 and $5,562 for controls in years 1 and 2 respectively (p < 0.05). Total unadjusted all cause medical costs in year 1 post-index for CB were $8,467, and $9,974 in year 2 compared to $4,385 and $4,617 for controls in years 1 and 2 respectively (p < 0.05).Total unadjusted CB costs in year 1 post-index for CB were $640, and $596 in year 2 (p < 0.05).

CONCLUSION:  CB cohort had greater resource use and costs compared to controls.

CLINICAL IMPLICATIONS:  Patients with CB need to be treated in order to prevent disease progression and healthcare burden.

DISCLOSURE:  Douglas Mapel, University grant monies None; Grant monies (from sources other than industry) None; Grant monies (from industry related sources) None; Shareholder GlaxoSmithKline; Employee Employee of GlaxoSmithKline; Fiduciary position (of any organization, association, society, etc, other than ACCP None; Consultant fee, speaker bureau, advisory committee, etc. None; Other None; No Product/Research Disclosure Information

Wednesday, November 4, 2009

12:45 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543